Every story we've covered involving swiss-companies.
A late-stage clinical trial failure for a cardiovascular drug developed by a Swiss pharmaceutical company has weighed heavily on Dow Jones futures, underperforming broader market indices like the S&P 500. The setback reflects investor concerns about the company's pipeline and future revenue prospects.
No stories here yet.